Effect of Dry Needling on Insulin Resistance in Obese Post Menopausal Women (Dry needle)

Effect of Dry Needling on Insulin Resistance in Obese Post- Menopausal Women

The aim of the study is to determine the effect Dry Needling of on insulin resistance in obese postmenopausal women.

Study Overview

• Status: Completed
• Conditions: Insulin Resistance-abdominal Fats -Post Menopausal Women
• Intervention / Treatment: Other: Dry Needle; Other: abdominal exercises, and medical standard care for insulin resistance

Detailed Description

Insulin resistance and abdominal obesity have a negative impact on quality of life of postmenopausal women. Obesity and, more specifically, the level of intra-abdominal fat, are positively associated with cardiovascular disease and cardiovascular disease risk factors such as increased plasma lipids and lipoproteins, hyperinsulinemia, and insulin resistance. This study has shown associations among menopause, body fat, and body fat distribution, suggesting that increased abdominal fat distribution could partially mediate the increased cardiovascular disease risk of postmenopausal women .

Abdominal obesity can reflect excess of visceral fat tissue or subcutaneous or both. Visceral fat contributes to the pathogenesis of glucose intolerance and insulin resistance. Insulin resistance is an impaired condition of glucose absorption that induced by insulin .It represents a significant medical and socioeconomic issue impacting women's health and quality of life. So there is clinical experience and documentation for the effectiveness of Dry Needling in the treatment of insulin resistance in obese post-menopausal women.

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt
    • Shymaa Mohammed

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• • All participants post-menopausal from at least 3 years.

  • All participants' ages will be ranged from 48-60 years old.
  • All participants BMI will exceed 25-30 kg/m2.
  • All participants waist hip ratio will be equal or more than 0, 90.

Exclusion Criteria:

• • Surgical liposuction within the last 12 months.

  • Untreated hypo- or hyperthyroidism.
  • Uncontrolled liver, kidney or cardiovascular disease or diabetes.
  • Implanted pacemaker or metal implant.
  • History of thrombophlebitis, any hematological disease.
  • No past or present neurological and musculoskeletal disorders that will have affected health condition.
  • No smoking and drinking habits.
  • No psychological problems.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dry Needle; 26 patients who were treated with Dry Needling (three times /week/4 months), abdominal exercises, and medical standard care for insulin resistance.	Other: Dry Needle; Dry Needle has been used to treat obesity. Clinical research has found that it is particularly effective for abdominal fat loss.Dry needling in the abdominal region requires an in-depth understanding of the underlying anatomy due to significant safety risks.; Other: abdominal exercises, and medical standard care for insulin resistance; To reduce belly fat, combine core-strengthening exercises like planks, bicycle crunches, and leg raises with overall fat-burning cardio (walking, running) and a healthy diet
Other: abdominal exercises and medical standard care for insulin resistance.; While Group (B), 26 patients treated with abdominal exercises and medical standard care for insulin resistance.	Other: abdominal exercises, and medical standard care for insulin resistance; To reduce belly fat, combine core-strengthening exercises like planks, bicycle crunches, and leg raises with overall fat-burning cardio (walking, running) and a healthy diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HOMA-IR	Outcome measures, HOMA-IR (Homeostasis Model Assessment) will be used to assess insulin resistance. HOMA-IR is a model of interactions between glucose and insulin dynamics that is then used to predict fasting steady-state glucose and insulin concentrations for a wide range of possible combinations of insulin resistance and β-cell function.	4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ultrasound	Abdominal fat thickness will be assessed by ultrasound (Aplio 500-model TUS-A500, fundamentals (2B77-004EN*M)	4 months
BMI by kg/m2	weight and height will be combined to report BMI in kg/m^2	4 months
waist circumferences by tape		4 months
The surface under the cumulative ranking curve (SUCRA)	The surface under the cumulative ranking curve (SUCRA) was used to rank and compare the effects of different types of exercise. SUCRA values range from 0 to 100, where 100 indicates the best treatment with no uncertainty and 0 indicates the worst treatment with no uncertainty. Thus, higher SUCRA values indicated the better effects of an exercise intervention prior to and after four-month treatment duration for both groups.	4 months

Collaborators and Investigators

• Sponsor: Cairo University
• Investigators: Principal Investigator: Shymaa Mohammed, out patient clinic ,faculty of physical therapy ,Cairo university ,Cairo,Egypt

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2025
• Primary Completion (Actual): April 1, 2025
• Study Completion (Actual): December 1, 2025

Study Registration Dates

• First Submitted: December 14, 2025
• First Submitted That Met QC Criteria: January 23, 2026
• First Posted (Actual): January 26, 2026

Study Record Updates

• Last Update Posted (Actual): January 26, 2026
• Last Update Submitted That Met QC Criteria: January 23, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: P.T.REC/012/006055

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No